GENITOURINARY CANCERS

>

Latest News

Extended PSA Monitoring Post-Prostatectomy May Reduce Overtreatment, Study Finds
Extended PSA Monitoring Post-Prostatectomy May Reduce Overtreatment, Study Finds

March 21st 2025

Investigators found that higher persistent PSA levels after surgery were linked to a worse prognosis, underscoring the importance of timing in post-operative care.

Updated Efficacy Shows Nivolumab Boosts Survival in High-Risk MIBC
Updated Efficacy Shows Nivolumab Boosts Survival in High-Risk MIBC

March 19th 2025

Phase 3 Trial of the ArteraAI Prostate Test Begins Enrollment
Phase 3 Trial of the ArteraAI Prostate Test Begins Enrollment

March 16th 2025

Novel rhPSMA Therapy Targets Advanced Prostate Cancer With Precision
Novel rhPSMA Therapy Targets Advanced Prostate Cancer With Precision

March 13th 2025

Gemcitabine-BCG Shows Early Promise in BCG-Exposed NMIBC
Gemcitabine-BCG Shows Early Promise in BCG-Exposed NMIBC

March 11th 2025

Latest CME Events & Activities

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

View More

Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management

View More

42nd Annual CFS: Chemotherapy Foundation Symposium®: Innovative Cancer Therapy for Tomorrow

View More

More News

FDA Approves Radium-223 for Advanced Prostate Cancer

FDA Approves Radium-223 for Advanced Prostate Cancer

Staff Writer
May 15th 2013

Radium RA 223 dichloride has been approved by the FDA for the treatment of symptomatic metastatic castration-resistant prostate cancer (mCRPC) that has spread to the bones but not to any other organs.

Read More

Using Radium-223 Plus Docetaxel in Patients With Bone Metastasis From CRPC

Using Radium-223 Plus Docetaxel in Patients With Bone Metastasis From CRPC

Michael J. Morris, MD
May 15th 2013

Michael J. Morris, MD, discusses an ongoing phase I/IIa study looking at radium-223 with docetaxel in patients with bone metastasis from castration-resistant prostate cancer.

Watch

Utilizing CTCs in Solid Tumors

Utilizing CTCs in Solid Tumors

Leonard G. Gomella, MD
May 10th 2013

Leonard G. Gomella, MD, from the Kimmel Cancer Center, discusses the utilization of circulating tumor cells in patients with solid tumors.

Watch

Findings From the COU-AA-302 Trial

Findings From the COU-AA-302 Trial

Howard I. Scher, MD
May 8th 2013

Howard I. Scher, MD, from the Memorial Sloan-Kettering Cancer Center, discusses an updated analysis of the COU-AA-302 trial.

Watch

The Role of Corticosteroids in Treatment Sequencing

The Role of Corticosteroids in Treatment Sequencing

William K. Oh, MD
April 10th 2013

William K. Oh, MD, Chief of the Division of Hematology and Medical Oncology, the Tisch Cancer Institute at Mount Sinai Medical Center, discusses sequencing treatment in patients with metastatic castration resistant prostate cancer.

Watch

<1
...
343536373839>